Related Experiment Video

Updated: Aug 25, 2025

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

767

Assessing cognitive behavioral therapy for insomnia in individuals with cannabis use disorder utilizing actigraphy

Luna Geagea1, Pia Maria Ghanimé1, Samer El Hayek2

  • 1Department of Psychiatry, American University of Beirut, Beirut, Lebanon.

Sleep Medicine
|October 16, 2022
PubMed

Insights

Cognitive Behavioral Therapy for insomnia (CBTi) effectively treats insomnia and anxiety in cannabis users. This therapy also shows potential in reducing cannabis use and inflammation.

Area of Science:

  • Psychiatry
  • Sleep Medicine
  • Addiction Medicine

Background:

  • Insomnia is a common issue in individuals with cannabis use disorder.
  • Inflammatory markers may be associated with insomnia symptoms in this population.

Purpose of the Study:

  • To assess the efficacy of Cognitive Behavioral Therapy for insomnia (CBTi) in individuals with cannabis use disorder and insomnia.
  • To investigate the impact of CBTi on serum inflammatory markers in relation to insomnia symptoms.

Main Methods:

  • Pilot study involving 19 participants with cannabis use disorder and insomnia.
  • Data collection included sleep parameters, cannabis use, inflammatory markers (IL-2, IL-6, CRP, cortisol), and validated questionnaires (ISI, PHQ-4).
  • Actigraphy was used to objectively measure sleep before and after CBTi.

Main Results:

  • CBTi significantly reduced insomnia severity (ISI scores) and improved sleep onset latency (SOL) as measured by actigraphy.
  • Participants reported decreased cannabis use and reduced anxiety/depression symptoms (PHQ-4 scores) post-CBTi.
  • A trend towards decreased levels of inflammatory markers (IL-2, IL-6, CRP) was observed 6 months after CBTi.

Conclusions:

  • CBTi is an effective short- and long-term treatment for insomnia and comorbid anxiety/depression in cannabis users.
  • CBTi may offer additional benefits, including reduced cannabis consumption and decreased inflammatory biomarkers.
Abstract

Keywords:
ActigraphyBiomarkersCannabisCognitive behavioral therapyInflammationInsomnia

More Related Videos

A Chronic Sleep Fragmentation Model using Vibrating Orbital Rotor to Induce Cognitive Deficit and Anxiety-Like Behavior in Young Wild-Type Mice06:23

A Chronic Sleep Fragmentation Model using Vibrating Orbital Rotor to Induce Cognitive Deficit and Anxiety-Like Behavior in Young Wild-Type Mice

Published on: September 22, 2020

5.4K
Collecting Sleep, Circadian, Fatigue, and Performance Data in Complex Operational Environments08:36

Collecting Sleep, Circadian, Fatigue, and Performance Data in Complex Operational Environments

Published on: August 8, 2019

12.1K

Related Concept Videos

Substance Use Disorders Affecting Sleep01:24

Substance Use Disorders Affecting Sleep

Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
210
Insomnia01:27

Insomnia

Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
118
Management of Insomnia01:19

Management of Insomnia

The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
312
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
423
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
231